Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
Revenue
Halozyme Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
Revenue
$1B
|
CAGR 3-Years
32%
|
CAGR 5-Years
39%
|
CAGR 10-Years
30%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Halozyme Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Halozyme Therapeutics Inc
|
Total Revenue:
1B
USD
|
|
United States:
690.5m
USD
|
|
Switzerland:
212.4m
USD
|
|
Belgium:
84m
USD
|
Breakdown by Segments
Halozyme Therapeutics Inc
|
Total Revenue:
1B
USD
|
|
Royalties:
571m
USD
|
|
Product Sales, Net:
303.5m
USD
|
|
Revenues Under Collaborative Agreements:
140.8m
USD
|
Halozyme Therapeutics Inc
Glance View
Halozyme Therapeutics Inc., a California-based biopharmaceutical company, weaves innovation with practicality in the realm of drug delivery. The narrative of Halozyme is centered around its proprietary enzyme technology, known as ENHANZE®. This platform is a transformative approach that leverages a recombinant human hyaluronidase enzyme, named rHuPH20. This enzyme temporarily degrades hyaluronan, a key component in the extracellular matrix, thereby allowing for quicker dispersal and absorption of subcutaneous drugs. By facilitating the transition of therapies from intravenous to subcutaneous administration, Halozyme not only enhances the patient experience with less clinic time and reduced infusion-related costs but also provides pharmaceutical partners with the opportunity to extend the lifecycle of their drugs. The company’s revenue generation resembles a carefully orchestrated symphony, harmonizing collaboration and licensing agreements with prominent pharmaceutical giants such as Roche and Bristol-Myers Squibb. Halozyme earns through a blend of upfront licensing fees, milestone payments, and royalties on product sales that incorporate the ENHANZE® technology. These alliances empower its partners to broaden the utility of their existing drug formulations, while Halozyme benefits from a steady cash inflow that supports its ongoing research and development activities. In essence, Halozyme’s business model thrives on creating value by enhancing drug delivery mechanisms, ensuring that its innovations are profitable not only for the partners it collaborates with but also for patients worldwide who benefit from its advancements.
See Also
What is Halozyme Therapeutics Inc's Revenue?
Revenue
1B
USD
Based on the financial report for Dec 31, 2024, Halozyme Therapeutics Inc's Revenue amounts to 1B USD.
What is Halozyme Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
30%
Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for Halozyme Therapeutics Inc have been 32% over the past three years , 39% over the past five years , and 30% over the past ten years .
You don't have any saved screeners yet